Information Provided By: 
Fly News Breaks for January 29, 2019
URGN
Jan 29, 2019 | 07:06 EDT
H.C. Wainwright analyst Raghuram Selvaraju started UroGen Pharma with a Buy rating and $82 price target. The company's technology platform, RTGel, is a novel targeted delivery system that permits instillation of both novel and existing approved active pharmaceutical ingredients into the urothelial tract to treat various conditions, including urothelial cancer, Selvaraju tells investors in a research note. This is a "transformative technology platform that significantly improves current therapy," adds the analyst.
News For URGN From the Last 2 Days
There are no results for your query URGN
